Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | MIR503HG | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of MIR503HG mRNA | CTD | PMID:31614463 | MIR503HG | Human | aflatoxin B1 | decreases methylation | EXP | | 6480464 | Aflatoxin B1 results in decreased methylation of MIR503HG gene | CTD | PMID:27153756 | MIR503HG | Human | arsenous acid | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of MIR503HG mRNA | CTD | PMID:26705709 | MIR503HG | Human | beta-naphthoflavone | decreases expression | EXP | | 6480464 | beta-Naphthoflavone results in decreased expression of MIR503HG mRNA | CTD | PMID:32858204 | MIR503HG | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of MIR503HG mRNA | CTD | PMID:25047013 | MIR503HG | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of MIR503HG mRNA | CTD | PMID:27392435 | MIR503HG | Human | dexamethasone | decreases expression | EXP | | 6480464 | Dexamethasone results in decreased expression of MIR503HG mRNA | CTD | PMID:25047013 | MIR503HG | Human | diarsenic trioxide | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of MIR503HG mRNA | CTD | PMID:26705709 | MIR503HG | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR503HG mRNA | CTD | PMID:27188386 | MIR503HG | Human | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of MIR503HG mRNA | CTD | PMID:27562236 | MIR503HG | Human | lead(0) | decreases expression | EXP | | 6480464 | Lead results in decreased expression of MIR503HG mRNA | CTD | PMID:37386098 | MIR503HG | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of MIR503HG mRNA | CTD | PMID:35811015 | MIR503HG | Human | nickel atom | increases expression | EXP | | 6480464 | Nickel results in increased expression of MIR503HG mRNA | CTD | PMID:25583101 | MIR503HG | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of MIR503HG mRNA | CTD | PMID:23557933 | MIR503HG | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of MIR503HG mRNA | CTD | PMID:35811015 | MIR503HG | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR503HG mRNA | CTD | PMID:27188386 | MIR503HG | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of MIR503HG mRNA | CTD | PMID:25493608 | MIR503HG | Human | triclosan | increases expression | EXP | | 6480464 | Triclosan results in increased expression of MIR503HG mRNA | CTD | PMID:30510588 | MIR503HG | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of MIR503HG gene | CTD | PMID:29154799 | MIR503HG | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of MIR503HG mRNA | CTD | PMID:26272509 and PMID:28001369 | MIR503HG | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR503HG mRNA | CTD | PMID:27188386 | MIR503HG | Human | zoledronic acid | decreases expression | EXP | | 6480464 | zoledronic acid results in decreased expression of MIR503HG mRNA | CTD | PMID:24714768 | |